A SGLT2 inhibitor (SGLT2i) acts directly on the kidney by inhibiting SGLT2 function thereby blocking the reabsorption of glucose and expelling excessive glucose in the urine, which eventually reduces hyperglycemia (12). The gene discussed is SLC5A2; the disease is Hyperglycemia.